Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Common antidepressants lower effects of tamoxifen in many women

20.01.2005


Additional evidence that a class of antidepressants can reduce the effectiveness of tamoxifen has been published by researchers from the Indiana University School of Medicine, the University of Michigan and Johns Hopkins University.



Results of the trial are published in the current issue of the Journal of the National Cancer Institute. The large clinical trial confirmed data from an earlier study showing that selective serotonin reuptake inhibitor antidepressants may hinder the effectiveness of tamoxifen, a drug commonly administered to breast cancer patients. The study also reports that researchers now have pinpointed genetic types that are linked with this effect.

Led by David Flockhart, M.D., Ph.D., an IU professor of medicine and director of the Division of Clinical Pharmacology, the researchers examined the effects of SSRIs in women who were prescribed tamoxifen to treat the common side effects of breast cancer therapy which include depression and hot flashes.


More than a fourth of the women enrolled in this study were prescribed SSRIs. The study showed that the various SSRIs taken by the women have different effects on the amount of active tamoxifen byproducts in their blood. "This is important because previous studies have shown that when tamoxifen is broken down, the resulting molecules are extremely powerful at blocking estrogen receptors and thereby exert a cancer-inhibitive effect," said Dr. Flockhart.

"We have withheld clinical recommendations, because at this point we don’t have final data," said Dr. Flockhart. The study makes clear that knowledge of a drug’s ability to inhibit CYP2D6 enzyme activity may help clinicians anticipate important drug interactions. Genetic testing may help identify a group of women who may experience greater benefit from tamoxifen or those who may benefit more from one SSRI than another, he said.

This study is the first large-scale clinical trial to determine the influence of multiple genetic variations and drug interactions on the plasma concentrations of tamoxifen and its active metabolites. "We can see the light at the end of the tunnel," said Dr. Flockhart. "Using our pharmacogenetic tool kit, we are very close to being able to identify which women should be given which drug to treat her depression or hot flashes."

PR Staff | EurekAlert!
Further information:
http://www.iupui.edu

More articles from Health and Medicine:

nachricht Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering

nachricht New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Data use draining your battery? Tiny device to speed up memory while also saving power

14.12.2018 | Power and Electrical Engineering

Tangled magnetic fields power cosmic particle accelerators

14.12.2018 | Physics and Astronomy

In search of missing worlds, Hubble finds a fast evaporating exoplanet

14.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>